Perrigo (PRGO) Cash from Financing Activities (2013 - 2026)

Perrigo (PRGO) reported Cash from Financing Activities of -$45.3 million for Q1 2026, up 26.7% year-over-year from -$35.8 million in Q1 2025, and up 16.73% quarter-over-quarter from -$54.4 million in Q4 2025.

Perrigo (PRGO) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Perrigo (PRGO) has 14 years of Cash from Financing Activities data on file, last reported at -$45.3 million in Q1 2026.

  • Cash from Financing Activities for Q1 2026 came in at -$45.3 million, up 26.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$204.0 million (up 66.69% YoY), and the FY2025 annual result was -$220.5 million, up 63.91% from the prior year.
  • Cash from Financing Activities improved to -$45.3 million in Q1 2026 per PRGO's latest filing, from -$54.4 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $653.3 million in Q3 2024 and troughed at -$1.2 billion in Q4 2024.
  • A 5-year average of -$37.8 million and a median of -$49.8 million in 2024 frame the typical range for Cash from Financing Activities.
  • On a YoY basis, Cash from Financing Activities climbed as much as 1608.78% in 2024 and fell as far as 2487.67% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$42.5 million in 2022, then retreated by 4.94% to -$44.6 million in 2023, then tumbled by 2487.67% to -$1.2 billion in 2024, then surged by 95.29% to -$54.4 million in 2025, then increased by 16.73% to -$45.3 million in 2026.
  • Business Quant data shows PRGO's Cash from Financing Activities at -$45.3 million in Q1 2026, -$54.4 million in Q4 2025, and -$50.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 13.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -840.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -1.48 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -86.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -65.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.47 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -77.88 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -11.62 Mn
10 Perrigo 1.55 Bn 1.19 Bn 325.50 Mn -45.30 Mn

Historic Data

Download Data
DateValue
Mar 28, 2026 -45.30 Mn
Mar 28, 2026 -45.30 Mn
Dec 31, 2025 -54.40 Mn
Dec 31, 2025 -54.40 Mn
Sep 27, 2025 -50.30 Mn
Sep 27, 2025 -50.30 Mn
Jun 28, 2025 -54.00 Mn
Jun 28, 2025 -54.00 Mn
Mar 29, 2025 -61.80 Mn
Mar 29, 2025 -61.80 Mn
Dec 31, 2024 -1.15 Bn
Dec 31, 2024 -1.15 Bn
Sep 28, 2024 653.30 Mn
Sep 28, 2024 653.30 Mn
Jun 29, 2024 -49.80 Mn
Jun 29, 2024 -49.80 Mn
Mar 30, 2024 -60.40 Mn
Mar 30, 2024 -60.40 Mn
Dec 31, 2023 -44.60 Mn
Dec 31, 2023 -44.60 Mn